Niacin modulates macrophage polarization in Parkinson's disease

J Neuroimmunol. 2018 Jul 15;320:76-79. doi: 10.1016/j.jneuroim.2018.05.002. Epub 2018 May 4.

Abstract

Neuroinflammation remains a central piece in Parkinson's disease (PD) pathophysiology. However, mechanisms by which PD links to the neuroinflammation remain elusive. Here, for the first time, we report that lower dose of niacin in PD patients may affect macrophage polarization from M1 (pro-inflammatory) to M2 (counter-inflammatory) profile through the niacin receptor GPR109A. Skew in the peripheral macrophages were accompanied by improved quality of life assessments in patients. Low dose niacin supplementation may be beneficial in PD, boosting anti-inflammatory processes and suppressing inflammation. Varied niacin dosages for longer durations may further reveal the potential role of anti-inflammatory interventions in PD progression.

Keywords: GPR109A; Macrophage polarization; Niacin; Parkinson's disease.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Aged
  • Dietary Supplements*
  • Female
  • Humans
  • Macrophages / drug effects
  • Macrophages / immunology*
  • Male
  • Middle Aged
  • Niacin / pharmacology*
  • Parkinson Disease / immunology*
  • Quality of Life*

Substances

  • Niacin